Image may be NSFW.
Clik here to view.
Clik here to view.
BioDelivery on track for mid-year NDA filing
BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Titan Pharma posts positive Phase 3 Probuphine results
Titan Pharmaceuticals (OTCQB:TTNP) has reported positive topline results from a Phase 3 double blind, double dummy clinical study of Probuphine, its subdermal implant containing buprenorphine HCl for...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Titan Pharma Phase 3 data validate ProNeura technology
Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid...
View Article
More Pages to Explore .....
